Comparable stake leader
GILEAD SCIENCES, INC.
SEC ownership of ASSEMBLY BIOSCIENCES, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001426800.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ASMB on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GILEAD SCIENCES, INC.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GILEAD SCIENCES, INC.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001426800
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ASSEMBLY BIOSCIENCES, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GILEAD SCIENCES, INC.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
50/50
Latest evidence
30 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 25%
13D/G row: GILEAD SCIENCES, INC.
Showing 1-8 of 50 holder rows.
Quick read
GILEAD SCIENCES, INC. leads the comparable SEC ownership view at 25%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GILEAD SCIENCES, INC.'s linked filing trail.
Comparable ownership
Top 5
GILEAD SCIENCES, INC.
25%
Commodore Capital LP
9.9%
RA CAPITAL MANAGEMENT, L.P.
9.5%
Janus Henderson Group Ltd.
8.2%
FARALLON CAPITAL MANAGEMENT, L.L.C.
8.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
3/4/5
13D/G
13F
10%+ Owner · Company
|
25%
from 13D/G
|
$138,114,219
7,273,009 shares
mixed-class rows
|
— | 26 May 2026 |
| Commodore Capital LP |
13D/G
13F
Company
|
9.9%
|
$29,281,576
1,615,981 shares
|
$0 | 08 Aug 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
9.5%
|
$28,392,908
1,530,615 shares
|
$0 | 11 Aug 2025 |
| Janus Henderson Group Ltd. |
13D/G
13F
JANUS HENDERSON GROUP PLC · Company
|
8.2%
|
$44,444,160
1,341,508 shares
|
$0 | 28 Nov 2025 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13D/G
13F
Company
|
8.1%
|
$46,484,972
1,604,590 shares
|
$0 | 30 Jun 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
7.8%
|
$38,963,707
1,227,590 shares
|
+$2,763,919 | 31 Dec 2025 |
| Paradigm Biocapital Advisors LP |
13F
13D/G
Company
|
5.4%
from 13D/G
|
$18,460,715
665,251 shares
|
— | 31 Mar 2026 |
| Alexander Schornstein |
3/4/5
13D/G
10%+ Owner
|
3.5%
from 13D/G
|
$10,812,478
728,113 shares
|
— | 22 Nov 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$14,687.
Buys
$0
Insiders: 0
Sells
$14,687
Insiders: 2
Net
-$14,687
Shares: -554
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 554
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 29 | $0 | $674 | -$674 |
| 3-6 | 0 | 525 | $0 | $14,012 | -$14,012 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to ASSEMBLY BIOSCIENCES, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
GILEAD SCIENCES, INC.
Net 12M change
-$14,687
Latest report
17 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10%+ Owner | $138,114,219 | Mixed | 26 May 2026 | ||
| Alexander Schornstein | 10%+ Owner | $10,812,478 | Filing P/S | 22 Nov 2024 | ||
| Jason A. Okazaki | CEO and President, Director | $5,034,570 | Mixed | 29 Mar 2026 | ||
| William E. Delaney IV | Chief Scientific Officer | $1,859,370 | Mixed | 29 Mar 2026 | ||
| Anuj Gaggar | Chief Medical Officer | $1,315,644 | Mixed | 29 Mar 2026 | ||
| Nicole S. White | Chief Manufacturing Officer | $1,030,242 | -$5,258 | -0.51% | Filing P/S | 29 Mar 2026 |
| Jeanette M. Bjorkquist | PFO and PAO | $338,520 | -$9,429 | -2.7% | Filing P/S | 17 Jun 2026 |
| John G. McHutchison | Director | $180,683 | Filing P/S | 04 Jun 2026 | ||
| Michael P. Samar | Chief Financial Officer | $61,782 | Mixed | 25 Jul 2022 | ||
| Michael Houghton | Director | $49,998 | Filing P/S | 04 Jun 2026 | ||
| Luisa M. Stamm | Chief Medical Officer | $32,252 | Mixed | 29 Mar 2022 | ||
| William R. Ringo | Director | Mixed | 05 Jun 2025 | |||
| Myron Z. Holubiak | Director | Mixed | 20 May 2021 | |||
| Gina Consylman | Director | Mixed | 04 Jun 2026 | |||
| Robert Donald Cook II | Director | Mixed | 13 Mar 2024 | |||
| Tomas Cihlar | Director | Mixed | 07 Dec 2023 | |||
| Richard D. DiMarchi | Director | Mixed | 25 May 2022 | |||
| Susan Mahony | Director | Mixed | 04 Jun 2026 | |||
| Lisa Johnson-Pratt | Director | Mixed | 04 Jun 2026 | |||
| Anthony E. Altig | Director | Mixed | 04 Jun 2026 |
Recent insider transactions for ASSEMBLY BIOSCIENCES, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jeanette M. Bjorkquist | ASMB | Common Stock | Sale | -0.2% | $674 | $23.25 | -29 | 14,560 | 17 Jun 2026 | Direct |
| John G. McHutchison | ASMB | Stock Option (right to buy) | Award | 8,000 | 8,000 | 04 Jun 2026 | Direct | |||
| Susan Mahony | ASMB | Stock Option (right to buy) | Award | 8,000 | 8,000 | 04 Jun 2026 | Direct | |||
| Lisa Johnson-Pratt | ASMB | Stock Option (right to buy) | Award | 8,000 | 8,000 | 04 Jun 2026 | Direct | |||
| Michael Houghton | ASMB | Stock Option (right to buy) | Award | 8,000 | 8,000 | 04 Jun 2026 | Direct | |||
| Gina Consylman | ASMB | Stock Option (right to buy) | Award | 8,000 | 8,000 | 04 Jun 2026 | Direct | |||
| Anthony E. Altig | ASMB | Stock Option (right to buy) | Award | 8,000 | 8,000 | 04 Jun 2026 | Direct | |||
| Gilead Sciences, Inc. | ASMB | Common Stock | Award | 10.5% | 471,698 | 4,977,089 | 26 May 2026 | Direct | ||
| Jeanette M. Bjorkquist | ASMB | Common Stock | Sale | -2.87% | $8,755 | $26.69 | -328 | 11,089 | 30 Mar 2026 | Direct |
| Nicole S. White | ASMB | Common Stock | Sale | -0.52% | $5,258 | $26.69 | -197 | 37,477 | 30 Mar 2026 | Direct |
| Anuj Gaggar | ASMB | Common Stock | Award | 48.8% | 14,000 | 42,688 | 29 Mar 2026 | Direct | ||
| Nicole S. White | ASMB | Common Stock | Award | 41% | 14,000 | 48,145 | 29 Mar 2026 | Direct | ||
| Jeanette M. Bjorkquist | ASMB | Common Stock | Award | 31.6% | 3,500 | 14,589 | 29 Mar 2026 | Direct | ||
| William E. Delaney IV | ASMB | Common Stock | Award | 30.2% | 14,000 | 60,330 | 29 Mar 2026 | Direct | ||
| Jason A. Okazaki | ASMB | Common Stock | Award | 45.1% | 50,750 | 163,354 | 29 Mar 2026 | Direct | ||
| Jeanette M. Bjorkquist | ASMB | Common Stock | Award | 132.2% | 6,500 | 11,417 | 29 Mar 2026 | Direct | ||
| Nicole S. White | ASMB | Common Stock | Award | 222.7% | 26,000 | 37,674 | 29 Mar 2026 | Direct | ||
| Anuj Gaggar | ASMB | Common Stock | Award | 1300% | 26,000 | 28,000 | 29 Mar 2026 | Direct | ||
| William E. Delaney IV | ASMB | Common Stock | Award | 132.4% | 26,000 | 45,642 | 29 Mar 2026 | Direct | ||
| Jason A. Okazaki | ASMB | Common Stock | Award | 533.5% | 94,250 | 111,916 | 29 Mar 2026 | Direct | ||
| Gilead Sciences, Inc. | ASMB | Common Stock | Purchase | 103.9% | 2,295,920 | 4,505,391 | 08 Aug 2025 | Direct | ||
| Gilead Sciences, Inc. | ASMB | Class B warrants to purchase Common Stock | Purchase | 1,147,960 | 1,147,960 | 08 Aug 2025 | Direct | |||
| Gilead Sciences, Inc. | ASMB | Class A warrants to purchase Common Stock | Purchase | 1,147,960 | 1,147,960 | 08 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.